Jim Wassil - 24 Feb 2022 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
Chief Operating Officer
Signature
/s/ Ron A. Metzger, Attorney-in-Fact
Issuer symbol
PCVX
Transactions as of
24 Feb 2022
Transactions value $
$-195,800
Form type
4
Filing time
28 Feb 2022, 16:17:37 UTC
Next filing
04 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Options Exercise $24,200 +10,000 +55.7% $2.42* 27,944 24 Feb 2022 Direct F1
transaction PCVX Common Stock Sale $-220,000 -10,000 -35.8% $22.00 17,944 24 Feb 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise $0 -10,000 -4.07% $0.000000 235,926 24 Feb 2022 Common Stock 10,000 $2.42 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1,563 shares acquired under the Issuer's Employee Stock Purchase Plan on May 17, 2021.
F2 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F3 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter.